首页 > 最新文献

International Journal of Tuberculosis and Lung Disease最新文献

英文 中文
Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0365
A A Pedersen, V N Dahl, A Løkke, I K Holden, A Fløe, R Ibsen, I S Johansen, O Hilberg

BACKGROUNDMortality and causes of death in non-tuberculous mycobacterial pulmonary disease (NTM-PD) are not well-described over long follow-up periods, particularly in Europe. We investigated whether NTM-PD is associated with higher mortality rates and different causes of death than matched controls.METHODSDanish national registers were used to identify patients with NTM-PD from 2000-2017 and to match them 1:4 with controls based on age, sex, cohabitation status, and municipality.RESULTSWe identified 661 patients with NTM-PD (50.4% male, median age 66 years, interquartile range [IQR] 48-84). The 5-year mortality rate for NTM-PD was 51% (95% CI 47-55) compared to 15% (95% CI 14-17) for controls. The hazard ratio (HR) of death for NTM-PD was 3.1 (95% CI 2.7-3.5; P < 0.001) compared to controls, persisting after adjusting for Charlson Comorbidity Index with an adjusted HR of 1.9 (95% CI 1.63-2.22; P < 0.001). Median age at death was 72 years (IQR 58-86) for NTM-PD patients and 81 years (IQR 69-93) for controls. Deaths due to respiratory diseases were more frequent in NTM-PD patients (45.2%) than in controls (11.6%). Mycobacterial infection directly caused death in 5.8% of NTM-PD patients.CONCLUSIONNTM-PD is associated with significantly higher all-cause mortality than controls, particularly in the initial years following diagnosis. These findings highlight the need for increased attention to NTM-PD and related respiratory conditions..

{"title":"Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease.","authors":"A A Pedersen, V N Dahl, A Løkke, I K Holden, A Fløe, R Ibsen, I S Johansen, O Hilberg","doi":"10.5588/ijtld.24.0365","DOIUrl":"https://doi.org/10.5588/ijtld.24.0365","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease (NTM-PD) are not well-described over long follow-up periods, particularly in Europe. We investigated whether NTM-PD is associated with higher mortality rates and different causes of death than matched controls.</sec><sec><title>METHODS</title>Danish national registers were used to identify patients with NTM-PD from 2000-2017 and to match them 1:4 with controls based on age, sex, cohabitation status, and municipality.</sec><sec><title>RESULTS</title>We identified 661 patients with NTM-PD (50.4% male, median age 66 years, interquartile range [IQR] 48-84). The 5-year mortality rate for NTM-PD was 51% (95% CI 47-55) compared to 15% (95% CI 14-17) for controls. The hazard ratio (HR) of death for NTM-PD was 3.1 (95% CI 2.7-3.5; <i>P</i> < 0.001) compared to controls, persisting after adjusting for Charlson Comorbidity Index with an adjusted HR of 1.9 (95% CI 1.63-2.22; <i>P</i> < 0.001). Median age at death was 72 years (IQR 58-86) for NTM-PD patients and 81 years (IQR 69-93) for controls. Deaths due to respiratory diseases were more frequent in NTM-PD patients (45.2%) than in controls (11.6%). Mycobacterial infection directly caused death in 5.8% of NTM-PD patients.</sec><sec><title>CONCLUSION</title>NTM-PD is associated with significantly higher all-cause mortality than controls, particularly in the initial years following diagnosis. These findings highlight the need for increased attention to NTM-PD and related respiratory conditions.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"60-66"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contamination effects in cluster randomised trials of TB interventions.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0275
K E LeGrand, K Allel, P Khan, R J Hayes, R G White, N McCreesh

BACKGROUNDCluster randomised trials (CRTs) of TB interventions have achieved mixed results, with many lacking significant reductions in outcomes. Contamination in CRTs, resulting from short and long-term movement between clusters and the general population, may dilute the impact of measured intervention.METHODSWe systematically reviewed the literature to identify CRTs that aimed to capture the population-level effects of the intervention on TB. Details of trial designs, interventions, outcomes, populations, cluster configurations, and geographic data were extracted to produce text summaries, descriptive statistics, and spatial analyses.RESULTSWe screened 1,039 abstracts and included 20 reports from seven CRTs. The median number of clusters was 32 (IQR 23-61), with populations ranging from 400-50,000 individuals per cluster. Four trials reported spatial data, from which the mean distance between clusters was 12.3 km (range 3.71-35.9). Several trials acknowledged design limitations, such as small cluster sizes and population mobility, which could have led to underestimations of intervention impact. Trials used various geographic, social, and pre-existing TB measures to select and allocate study clusters. Data on the potential for contamination are inconsistent.CONCLUSIONGaps remain in the reporting of methods and results, suggesting necessary improvements to standardised reporting tools. These insights can inform recommendations for improved CRT design and reporting practices..

{"title":"Contamination effects in cluster randomised trials of TB interventions.","authors":"K E LeGrand, K Allel, P Khan, R J Hayes, R G White, N McCreesh","doi":"10.5588/ijtld.24.0275","DOIUrl":"https://doi.org/10.5588/ijtld.24.0275","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>Cluster randomised trials (CRTs) of TB interventions have achieved mixed results, with many lacking significant reductions in outcomes. Contamination in CRTs, resulting from short and long-term movement between clusters and the general population, may dilute the impact of measured intervention.</sec><sec><title>METHODS</title>We systematically reviewed the literature to identify CRTs that aimed to capture the population-level effects of the intervention on TB. Details of trial designs, interventions, outcomes, populations, cluster configurations, and geographic data were extracted to produce text summaries, descriptive statistics, and spatial analyses.</sec><sec><title>RESULTS</title>We screened 1,039 abstracts and included 20 reports from seven CRTs. The median number of clusters was 32 (IQR 23-61), with populations ranging from 400-50,000 individuals per cluster. Four trials reported spatial data, from which the mean distance between clusters was 12.3 km (range 3.71-35.9). Several trials acknowledged design limitations, such as small cluster sizes and population mobility, which could have led to underestimations of intervention impact. Trials used various geographic, social, and pre-existing TB measures to select and allocate study clusters. Data on the potential for contamination are inconsistent.</sec><sec><title>CONCLUSION</title>Gaps remain in the reporting of methods and results, suggesting necessary improvements to standardised reporting tools. These insights can inform recommendations for improved CRT design and reporting practices.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"47-53"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stool-based Xpert testing for diagnosis of TB in children and critically ill adults.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0349
W Mwanza, M Lutinala, K Mundia, E Klinkenberg, P de Haas, M Kabaso, K Zimba, C Chabala, B Tambatamba, M Angel, P Lungu, K Lishimpi

BACKGROUNDWe describe our approach and experience with the routine implementation of stool-based Xpert MTB/RIF Ultra (Xpert) testing for the diagnosis of childhood TB in Zambia.METHODSWe conducted a method validation and subsequently introduced stool as an alternative sample for routine Xpert testing for children and critically ill adults. We reviewed the impact of stool-based Xpert testing during the first 18 months of routine implementation.RESULTSThe method validation showed 98.0% (95% CI 92.9-99.4) agreement between Xpert results on sputum/gastric aspirate (GA) and stool specimens. During 18 months of routine implementation, 16,210 stool samples were tested, yielding 157 TB cases in children, including five rifampicin (RIF) resistant cases, and 45 cases in critically ill adults. In children aged 0-4 years, 10,288 stool samples were tested compared to 2,459 GA samples in the same period. Childhood TB notifications and the bacteriological confirmation rate increased by 30% and 53%, respectively, in 2021 compared to 2020.CONCLUSIONThe routine implementation of stool testing provided access to Xpert testing for children who could not produce sputum or have GA collected, contributing to increased bacteriological confirmation of TB in children. For critically ill adults with difficulty expectorating sputum, it facilitated a rapid test result..

{"title":"Stool-based Xpert testing for diagnosis of TB in children and critically ill adults.","authors":"W Mwanza, M Lutinala, K Mundia, E Klinkenberg, P de Haas, M Kabaso, K Zimba, C Chabala, B Tambatamba, M Angel, P Lungu, K Lishimpi","doi":"10.5588/ijtld.24.0349","DOIUrl":"https://doi.org/10.5588/ijtld.24.0349","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>We describe our approach and experience with the routine implementation of stool-based Xpert MTB/RIF Ultra (Xpert) testing for the diagnosis of childhood TB in Zambia.</sec><sec><title>METHODS</title>We conducted a method validation and subsequently introduced stool as an alternative sample for routine Xpert testing for children and critically ill adults. We reviewed the impact of stool-based Xpert testing during the first 18 months of routine implementation.</sec><sec><title>RESULTS</title>The method validation showed 98.0% (95% CI 92.9-99.4) agreement between Xpert results on sputum/gastric aspirate (GA) and stool specimens. During 18 months of routine implementation, 16,210 stool samples were tested, yielding 157 TB cases in children, including five rifampicin (RIF) resistant cases, and 45 cases in critically ill adults. In children aged 0-4 years, 10,288 stool samples were tested compared to 2,459 GA samples in the same period. Childhood TB notifications and the bacteriological confirmation rate increased by 30% and 53%, respectively, in 2021 compared to 2020.</sec><sec><title>CONCLUSION</title>The routine implementation of stool testing provided access to Xpert testing for children who could not produce sputum or have GA collected, contributing to increased bacteriological confirmation of TB in children. For critically ill adults with difficulty expectorating sputum, it facilitated a rapid test result.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"75-79"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0311
B Tchakounte Youngui, B K Tchounga, D Atwine, A Vasiliu, B Cuer, L Simo, R Okello, P Tchendjou, A Kuate Kuate, S Turyahabwe, J Cohn, S M Graham, M Casenghi, M Bonnet

BACKGROUNDThe WHO recommends shorter TB preventive treatment (TPT) regimens and decentralised delivery models to improve effectiveness. This study evaluated the safety of a 3-month rifampicin-isoniazid (3RH) regimen administered by community health workers (CHWs) in households in Cameroon and Uganda.METHODSA cluster-randomised trial was conducted among child contacts of TB patients. We compared the safety of 3RH delivered by CHWs at home (intervention) vs standard-of-care, facility-based administration of 3RH. Safety outcomes included adverse events (AEs), serious adverse events (SAEs), and adverse reactions (ARs). We described the steps from symptom identification by CHWs to classification by a clinician.RESULTSOf 1,316 children initiated on 3RH, AEs were reported in 8.7% (81/936) in the intervention arm versus 11.3% (43/380) in the standard-of-care arm, P = 0.15. Overall, 37 SAEs occurred in 36 children, all non-medication related. There were 16 ARs reported, occurring in 1.0% (9/936) of children in the intervention arm and 1.6% (6/380) in the standard-of-care arm, P = 0.22. During 4,608 follow-up visits, 21 children reporting AR symptoms were identified by CHWs, 16 were assessed by clinicians, and 4 ARs were confirmed.CONCLUSIONSThe 3RH regimen was safe, including when administered by trained CHWs in community settings, supporting its use in decentralised healthcare models..

{"title":"Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention.","authors":"B Tchakounte Youngui, B K Tchounga, D Atwine, A Vasiliu, B Cuer, L Simo, R Okello, P Tchendjou, A Kuate Kuate, S Turyahabwe, J Cohn, S M Graham, M Casenghi, M Bonnet","doi":"10.5588/ijtld.24.0311","DOIUrl":"https://doi.org/10.5588/ijtld.24.0311","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>The WHO recommends shorter TB preventive treatment (TPT) regimens and decentralised delivery models to improve effectiveness. This study evaluated the safety of a 3-month rifampicin-isoniazid (3RH) regimen administered by community health workers (CHWs) in households in Cameroon and Uganda.</sec><sec><title>METHODS</title>A cluster-randomised trial was conducted among child contacts of TB patients. We compared the safety of 3RH delivered by CHWs at home (intervention) vs standard-of-care, facility-based administration of 3RH. Safety outcomes included adverse events (AEs), serious adverse events (SAEs), and adverse reactions (ARs). We described the steps from symptom identification by CHWs to classification by a clinician.</sec><sec><title>RESULTS</title>Of 1,316 children initiated on 3RH, AEs were reported in 8.7% (81/936) in the intervention arm versus 11.3% (43/380) in the standard-of-care arm, <i>P</i> = 0.15. Overall, 37 SAEs occurred in 36 children, all non-medication related. There were 16 ARs reported, occurring in 1.0% (9/936) of children in the intervention arm and 1.6% (6/380) in the standard-of-care arm, <i>P</i> = 0.22. During 4,608 follow-up visits, 21 children reporting AR symptoms were identified by CHWs, 16 were assessed by clinicians, and 4 ARs were confirmed.</sec><sec><title>CONCLUSIONS</title>The 3RH regimen was safe, including when administered by trained CHWs in community settings, supporting its use in decentralised healthcare models.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"67-74"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to 'Rethinking latent TB? Think again'.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0486
M A Behr, P H Edelstein, L Ramakrishnan
{"title":"Response to 'Rethinking latent TB? Think again'.","authors":"M A Behr, P H Edelstein, L Ramakrishnan","doi":"10.5588/ijtld.24.0486","DOIUrl":"https://doi.org/10.5588/ijtld.24.0486","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"95-96"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0383
I Bouzouita, A M Cabibbe, A Ghariani, S Smaoui, H Draoui, S Bejaoui, K B Dhaou, F Messadi, F Tritar, D M Cirillo, E Mehiri, L Slim-Saidi
{"title":"First report of multidrug-resistant <i>M. tuberculosis</i> Beijing strain isolated from the indigenous population in Tunisia.","authors":"I Bouzouita, A M Cabibbe, A Ghariani, S Smaoui, H Draoui, S Bejaoui, K B Dhaou, F Messadi, F Tritar, D M Cirillo, E Mehiri, L Slim-Saidi","doi":"10.5588/ijtld.24.0383","DOIUrl":"https://doi.org/10.5588/ijtld.24.0383","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"92-94"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BMI as a predictor of progression from TB infection to active TB in PLHIV.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0287
D Nguenha, F Ndebele, B Saavedra, E Mambuque, S Acácio, V Cárdenas, V Chihota, A Grant, G Yimer, K Fielding, F Cobelens, G Churchyard, A L Garcia-Basteiro

BACKGROUNDLow body mass index (BMI) is a globally important risk factor for TB progression. Little is known about this association in people living with HIV (PLHIV) and the functional form of the BMI-TB incidence curve.METHODSSecondary analysis of a randomised controlled trial of TB preventive therapy among PLHIV in South Africa, Mozambique, and Ethiopia. Participants received 3 months of weekly high-dose rifapentine-isoniazid given once or twice over a period of 2 years. Multivariable fractional polynomials (MFPs) were used to investigate functional forms of BMI. Time to incident TB was modelled using Cox's proportional hazard regression.RESULTSA total of 76 TB events were documented, giving an overall TB incidence rate of 1.2 per 100 person-years (95%CI 1.0-1.6). Baseline BMI <18.5 kg/m² was associated with a 2.6-fold increased hazard of TB compared with BMI 18.5-24.9 kg/m² (aHR 2.6, 95% CI 1.4-4.8, P < 0.001). BMI ≥30 kg/m² was associated with a lower hazard of TB (aHR 0.5, 95% CI 0.2-1.0). Continuous and categorical BMI showed weak evidence of quadratic dose-response relationships (P = 0.08 and P = 0.09, respectively). MFP analysis was consistent with a decline in TB incidence for increasing BMI to around 25 kg/m², followed by a less steep decline in TB incidence for increasing BMI >25 kg/m².CONCLUSIONSIn PLHIV, BMI showed an inverse log-linear association with TB incidence. The MFP approach showed that the relationship is more complex than a simple log-linear association..

{"title":"BMI as a predictor of progression from TB infection to active TB in PLHIV.","authors":"D Nguenha, F Ndebele, B Saavedra, E Mambuque, S Acácio, V Cárdenas, V Chihota, A Grant, G Yimer, K Fielding, F Cobelens, G Churchyard, A L Garcia-Basteiro","doi":"10.5588/ijtld.24.0287","DOIUrl":"https://doi.org/10.5588/ijtld.24.0287","url":null,"abstract":"<p><p><sec><title>BACKGROUND</title>Low body mass index (BMI) is a globally important risk factor for TB progression. Little is known about this association in people living with HIV (PLHIV) and the functional form of the BMI-TB incidence curve.</sec><sec><title>METHODS</title>Secondary analysis of a randomised controlled trial of TB preventive therapy among PLHIV in South Africa, Mozambique, and Ethiopia. Participants received 3 months of weekly high-dose rifapentine-isoniazid given once or twice over a period of 2 years. Multivariable fractional polynomials (MFPs) were used to investigate functional forms of BMI. Time to incident TB was modelled using Cox's proportional hazard regression.</sec><sec><title>RESULTS</title>A total of 76 TB events were documented, giving an overall TB incidence rate of 1.2 per 100 person-years (95%CI 1.0-1.6). Baseline BMI <18.5 kg/m² was associated with a 2.6-fold increased hazard of TB compared with BMI 18.5-24.9 kg/m² (aHR 2.6, 95% CI 1.4-4.8, <i>P</i> < 0.001). BMI ≥30 kg/m² was associated with a lower hazard of TB (aHR 0.5, 95% CI 0.2-1.0). Continuous and categorical BMI showed weak evidence of quadratic dose-response relationships (<i>P</i> = 0.08 and <i>P</i> = 0.09, respectively). MFP analysis was consistent with a decline in TB incidence for increasing BMI to around 25 kg/m², followed by a less steep decline in TB incidence for increasing BMI >25 kg/m².</sec><sec><title>CONCLUSIONS</title>In PLHIV, BMI showed an inverse log-linear association with TB incidence. The MFP approach showed that the relationship is more complex than a simple log-linear association.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"54-59"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversible zoonotic transmission of TB from humans to dairy cattle.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0368
M N Islam, M K Khan, J Hassan, M S Nahar, M F R Khan, M A Islam, A K M A Rahman, M M Alam

OBJECTIVETo use molecular techniques to assess the prevalence of M. bovis and M. tuberculosis in tuberculin-positive dairy cattle and to identify the risk factors for TB in these animals.METHODSA cross-sectional study was conducted from 2018 to 2020 across Mymensingh, Sirajgonj and Dhaka Districts in Bangladesh. The single intradermal comparative cervical tuberculin test was administered to 1,580 cattle suspected of having bovine TB using both avian and bovine purified protein derivative. Milk and lung tissue samples from positive animals were examined using polymerase chain reaction (PCR) to detect the causative agents of TB. Multivariable logistic regression model identified risk factors, and Sanger's dideoxy sequencing method was used for the phylogenetic analysis of PCR amplicons.RESULTSSimplex PCR identified Mycobacterium tuberculosis complex in 12.6% of samples. Multiplex PCR detected M. bovis in 6.3% and M. tuberculosis in 3.1% of the samples. Phylogenetic analysis of 12 IS6110 gene sequences (8 M. bovis, 4 M. tuberculosis) confirmed alignment with human isolates from Bangladesh.CONCLUSIONThe study suggests potential reverse zoonotic transmission of M. tuberculosis. Further research is needed to understand the implications and assess TB transmission between humans and cattle in Bangladesh. The findings highlight the need for a comprehensive One Health approach..

{"title":"Reversible zoonotic transmission of TB from humans to dairy cattle.","authors":"M N Islam, M K Khan, J Hassan, M S Nahar, M F R Khan, M A Islam, A K M A Rahman, M M Alam","doi":"10.5588/ijtld.24.0368","DOIUrl":"https://doi.org/10.5588/ijtld.24.0368","url":null,"abstract":"<p><p><sec><title>OBJECTIVE</title>To use molecular techniques to assess the prevalence of <i>M. bovis</i> and <i>M. tuberculosis</i> in tuberculin-positive dairy cattle and to identify the risk factors for TB in these animals.</sec><sec><title>METHODS</title>A cross-sectional study was conducted from 2018 to 2020 across Mymensingh, Sirajgonj and Dhaka Districts in Bangladesh. The single intradermal comparative cervical tuberculin test was administered to 1,580 cattle suspected of having bovine TB using both avian and bovine purified protein derivative. Milk and lung tissue samples from positive animals were examined using polymerase chain reaction (PCR) to detect the causative agents of TB. Multivariable logistic regression model identified risk factors, and Sanger's dideoxy sequencing method was used for the phylogenetic analysis of PCR amplicons.</sec><sec><title>RESULTS</title>Simplex PCR identified <i>Mycobacterium tuberculosis</i> complex in 12.6% of samples. Multiplex PCR detected <i>M. bovis</i> in 6.3% and <i>M. tuberculosis</i> in 3.1% of the samples. Phylogenetic analysis of 12 IS<i>6110</i> gene sequences (8 <i>M. bovis</i>, 4 <i>M. tuberculosis</i>) confirmed alignment with human isolates from Bangladesh.</sec><sec><title>CONCLUSION</title>The study suggests potential reverse zoonotic transmission of <i>M. tuberculosis</i>. Further research is needed to understand the implications and assess TB transmission between humans and cattle in Bangladesh. The findings highlight the need for a comprehensive One Health approach.</sec>.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"80-87"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sputum pooling for rapid and cost-effective active case-finding for TB in prisons.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0358
D Batestin, C Busatto, A D Salindri, A da Silva Santos, I B Gonçalves Lemes, P C Pereira Dos Santos, E F Lemos, T O Gonçalves, E A T Cunha, R D de Oliveira, J R Andrews, J Croda
{"title":"Sputum pooling for rapid and cost-effective active case-finding for TB in prisons.","authors":"D Batestin, C Busatto, A D Salindri, A da Silva Santos, I B Gonçalves Lemes, P C Pereira Dos Santos, E F Lemos, T O Gonçalves, E A T Cunha, R D de Oliveira, J R Andrews, J Croda","doi":"10.5588/ijtld.24.0358","DOIUrl":"https://doi.org/10.5588/ijtld.24.0358","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"88-89"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chest X-ray scoring to screen for chronic pulmonary aspergillosis in patients with a history of pulmonary TB.
IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2025-02-01 DOI: 10.5588/ijtld.24.0433
A S Ali, S M Zubair, K Jabeen, M Irfan
{"title":"Chest X-ray scoring to screen for chronic pulmonary aspergillosis in patients with a history of pulmonary TB.","authors":"A S Ali, S M Zubair, K Jabeen, M Irfan","doi":"10.5588/ijtld.24.0433","DOIUrl":"https://doi.org/10.5588/ijtld.24.0433","url":null,"abstract":"","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 2","pages":"90-91"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Tuberculosis and Lung Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1